Scarica l'app Stockscreener
2.65
7.02%
-0.20
Dopo l'orario di chiusura:
2.55
-0.10
-3.77%
Precedente Chiudi:
$2.85
Aprire:
$2.81
Volume 24 ore:
164.92K
Relative Volume:
1.15
Capitalizzazione di mercato:
$38.91M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.99%
1M Prestazione:
+44.02%
6M Prestazione:
-73.12%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.52
$2.89
Intervallo di 1 settimana:
$2.52
$3.1497
Portata 52W:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Confronta OKUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.65 | 38.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
Two Sigma Advisers LP Invests $122,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Northern Trust Corp Purchases New Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position - TipRanks
Bank of America Corp DE Takes $2.15 Million Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Elects Directors at Annual Stockholder Meeting - TipRanks
OnKure Therapeutics (NASDAQ:OKUR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Major Stakeholders Shuffle Shares in OnKure Therapeutics - TipRanks
OnKure Therapeutics Inc (OKUR) At $2.00 Is Well Worth Your Time - Stocksregister
Barclays PLC Purchases New Stake in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Major Shareholder Sells Thousands of OnKure Therapeutics Shares! - TipRanks
Leerink Partnrs Issues Optimistic Outlook for OKUR Earnings - Defense World
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics - TipRanks
OnKure increased R&D spending in 1Q with drug trials underway - BizWest
OnKure Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Form 424B3 OnKure Therapeutics, - StreetInsider
OnKure Therapeutics Reports Progress in PIKture-01 Trial and Financial Results for Q1 2025 - Nasdaq
OnKure Therapeutics, Inc. SEC 10-Q Report - TradingView
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Head to Head Contrast: OnKure Therapeutics (NASDAQ:OKUR) & Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics (OKUR) Projected to Post Earnings on Tuesday - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Research Coverage Started at Evercore ISI - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World
Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com
Evercore ISI starts OnKure stock with Outperform rating - Investing.com
Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India
OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com
OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia
OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa
OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India
OnKure Therapeutics CFO sells $9,177 in stock - Investing.com
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada
OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Non sono disponibili dati finanziari per Onkure Therapeutics Inc (OKUR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):